If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g Vct5 Regulatory News (MIG5)

Share Price Information for Maven I&g Vct5 (MIG5)

Share Price is delayed by 15 minutes
Get Live Data
28.00    0.00 (0.00%)
Bid:
27.00
Ask:
29.00
Spread: 2.00 (7.407%)
Market Cap: £74.17m
MIG5 Live PriceLast checked at - London Stock Exchange

Intraday Maven I&g Vct5 Share Chart

Issue of Equity

24 Mar 2026 12:13

RNS Number : 9352X
Maven Income and Growth VCT 5 PLC
24 March 2026
 

Maven Income and Growth VCT 5 PLC

(the Company)

 

Issue of Equity

 

On 2 October 2025, the Company launched an offer for subscription for new ordinary shares of 10p each (Ordinary Shares) to raise up to £7.5 million, with an over-allotment facility for up to a further £5 million (the Offer).

 

Pursuant to the Offer, a total of £2,903,849 of valid applications were received in the period from 9.00am on 12 February 2026 up to and including 9.00am on 19 March 2026 in respect of the 2025/2026 tax year. As a result, the Company has issued and allotted 9,220,907 new Ordinary Shares on 24 March 2026. In accordance with the allotment formula set out in the prospectus for the Offer, the offer prices at which the shares were issued were in the range of 30.58p to 31.39p per Ordinary Share and, as a result, the number of Ordinary Shares now in issue is 260,096,992. Therefore, the total number of voting rights in the Company is 260,096,992 and this may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

In respect of this allotment, an application will be made by the Company to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on the London Stock Exchange's main market for listed securities. It is expected that the admission of the new Ordinary Shares will become effective, and dealings will commence, on or around 25 March 2026.

 

This is the third allotment in respect of the 2025/2026 tax year, and the Board of the Company intends that a further allotment in respect of applications for the 2025/2026 tax year will take place on 2 April 2026. It is also intended that an allotment in respect of applications for the 2026/2027 tax year will take place on, or before, 30 April 2026. The Company's Offer has, to date, received applications totalling £12,383,552 for both tax years.

 

For further information, please contact:

 

Maven Capital Partners UK LLP

Telephone: 0141 306 7400

E-mail: enquiries@mavencp.com

 

Maven Capital Partners UK LLP

Secretary

 

24 March 2026

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEAKQBDBBKDDNB
Date   Source Headline
1st Apr 202512:59 pmRNSStatement re Offers for Subscription - Closed
27th Mar 20251:14 pmRNSDirector/PDMR Shareholding
27th Mar 20251:09 pmRNSIssue of Equity
27th Mar 202510:25 amRNSUpdate re: Offers for Subscription
21st Mar 20254:35 pmRNSNet Asset Value(s)
12th Mar 20254:54 pmRNSAnnual Financial Report
26th Feb 20254:41 pmRNSTransaction in Own Shares
26th Feb 202510:33 amRNSUnaudited NAV and Proposed Final Dividend
19th Feb 202510:12 amRNSIssue of Equity
28th Jan 202512:15 pmRNSStatement re Offer for Subscription
18th Dec 20249:35 amRNSIssue of Equity
17th Dec 20243:27 pmRNSDirectorate Change
13th Dec 20242:45 pmRNSUnaudited Net Asset Value
14th Nov 20242:58 pmRNSResult of General Meeting
8th Oct 20245:01 pmRNSTransaction in Own Shares
4th Oct 20244:18 pmRNSTransaction in Own Shares
27th Sep 20244:31 pmRNSPublication of a Prospectus
6th Sep 20249:47 amRNSIssue of Equity
5th Sep 20242:28 pmRNSStatement re Dividend Investment Scheme
5th Sep 20241:36 pmRNSUnaudited Net Asset Value
12th Jul 20244:37 pmRNSTransaction in Own Shares
12th Jul 20244:09 pmRNSHalf-year Report
10th Jul 20245:05 pmRNSTransaction in Own Shares
5th Jul 202412:38 pmRNSStatement re NAV and Interim Dividend
18th Jun 202411:53 amRNSStatement re Intended Offers for Subscription
9th May 20244:05 pmRNSTransaction in Own Shares
3rd May 20249:28 amRNSIssue of Equity
1st May 202410:10 amRNSIssue of Equity
26th Apr 20242:44 pmRNSUnaudited NAV - Dividend Investment Scheme
23rd Apr 20242:27 pmRNSResult of AGM
19th Apr 202412:17 pmRNSIssue of Supplementary Prospectus
5th Apr 20243:49 pmRNSIssue of Equity
27th Mar 202410:31 amRNSIssue of Equity
22nd Mar 20244:25 pmRNSStatement re Offer for Subscription
22nd Mar 202410:14 amRNSIssue of Supplementary Prospectus
20th Mar 20243:48 pmRNSUnaudited Net Asset Value
8th Mar 20242:57 pmRNSAnnual Financial Report
15th Feb 20244:45 pmRNSTransaction in Own Shares
8th Feb 202410:33 amRNSDirector/PDMR Shareholding
8th Feb 202410:12 amRNSIssue of Equity
7th Feb 20243:09 pmRNSDividend Declaration
19th Dec 20233:28 pmRNSIssue of Equity
18th Dec 20235:24 pmRNSUnaudited Net Asset Value
9th Nov 20233:51 pmRNSResult of General Meeting
20th Oct 20234:13 pmRNSTransaction in Own Shares
13th Oct 20234:56 pmRNSPublication of a Prospectus
4th Oct 20234:03 pmRNSNet Asset Value(s)
29th Aug 20239:15 amRNSDirectorate Change
24th Jul 202311:16 amRNSHalf-year Report
21st Jul 20234:43 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.